Abbvie Inc Common Stock (ABBV) 64.86 $ABBV Testosterone

New Post Public Reply Private Reply Replies (0) Message Board

Jul 13, 2016 at 4:01 PM

Abbvie Inc Common Stock (ABBV) 64.86 $ABBV

Testosterone Replacement Therapy (TRT) Market to Face Lean Patch until 2024 as it Inches Close to Patent Cliff, Says TMR
PR Newswire Europe - Tue Jul 12, 11:31AM CDT
ALBANY, New York, July 12, 2016 /PRNewswire/ --
AGN: 241.20 (+1.50), ENDP: 17.30 (-0.09), LLY: 79.48 (-0.19), ABBV: 64.86 (-0.64)

AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:19AM CDT
AbbVie's (ABBV) ABT-414 has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with EGFR-amplified DIPG.
INVA: 11.88 (+0.12), GWPH: 92.23 (-4.87), SGEN: 41.44 (-1.10), ABBV: 64.86 (-0.64)

Amgen Humira Biosimilar Briefing Documents Look Good
Arpita Dutt - Zacks Investment Research - Mon Jul 11, 7:04AM CDT
An FDA advisory panel will be meeting tomorrow to review Amgen Inc.'s (AMGN) ABP 501, a biosimilar version of AbbVie's Humira.
INVA: 11.88 (+0.12), FCSC: 1.17 (-0.02), AMGN: 160.64 (-1.32), ABBV: 64.86 (-0.64)

UCB's Vimpat Approved in Japan for Partial Onset Seizures
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:47AM CDT
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
JNJ: 122.99 (+0.07), ABBV: 64.86 (-0.64), NVS: 82.09 (+0.41)

Amgen's Kyprolis Gains Approval in EU for Label Expansion
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:37AM CDT
Amgen's (AMGN) Kyprolis label has been expanded in the EU for the treatment of relapsed multiple myeloma patients.
AMGN: 160.64 (-1.32), ABBV: 64.86 (-0.64), BMY: 76.72 (+0.52), CELG: 101.93 (-1.48)

Blog Coverage Biotech Major Medivation Open to Takeover Talks
ACCESSWIRE - Wed Jul 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / July 6, 2016 / Active Wall St. blog coverage looks at the headline from Medivation Inc. (NASDAQ: MDVN) as the U.S. company signs confidentiality agreements with Paris-based Sanofi S.A. (NYSE: SNY), Pfizer Inc. (NYSE: PFE) and Celgene Corp. (NASDAQ: CELG) among others. Register with us now for your free membership and blog access at:
MDVN: 61.64 (-0.51), PFE: 36.31 (+0.07), ABBV: 64.86 (-0.64), SNY: 42.11 (-0.39), CELG: 101.93 (-1.48)

Biogen and AbbVie's Once-Monthly ZINBRYTA(TM) (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
BusinessWire - Tue Jul 05, 7:00AM CDT
--- Targeted Mechanism of Action of ZINBRYTA Did Not Cause Broad, Prolonged Depletion of Studied Immune Cell Types -
BIIB: 251.41 (-1.95), ABBV: 64.86 (-0.64)

Dow 30 Stock Roundup: Nike Beats on Earnings, AmEx Raises Dividend
Swarup Gupta - Zacks Investment Research - Mon Jul 04, 8:43AM CDT
The Dow staged a spectacular rebound last week following losses after a surprise Brexit verdict.
JNJ: 122.99 (+0.07), GE: 32.39 (+0.13), MDLZ: 45.66 (-0.07), GS: 158.12 (+1.20), AXP: 63.09 (+0.09), NKE: 57.99 (-0.07), HSY: 108.76 (+0.02), ABBV: 64.86 (-0.64), INTC: 35.08 (+0.14), CSCO: 29.81 (+0.20)

Owens-Illinois, Korn Ferry, AbbVie and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:30AM CDT
Owens-Illinois, Korn Ferry, AbbVie and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
JNJ: 122.99 (+0.07), OI: 17.93 (+0.05), ABBV: 64.86 (-0.64), KFY: 22.68 (+0.27)

AbbVie Humira Gains FDA Approval for Yet Another Indication
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:04AM CDT
AbbVie's (ABBV) Humira label expanded in the U.S.; the drug can now be used for the treatment of adults with non-infectious intermediate, posterior and panuveitis.
JNJ: 122.99 (+0.07), PFE: 36.31 (+0.07), ABBV: 64.86 (-0.64), BMY: 76.72 (+0.52)

AbbVie, J&J's Imbruvica Gets Breakthrough Therapy Status
Arpita Dutt - Zacks Investment Research - Thu Jun 30, 8:38AM CDT
This is the 4th breakthrough therapy designation for the AbbVie (ABBV) and J&J drug.
JNJ: 122.99 (+0.07), PFE: 36.31 (+0.07), ABBV: 64.86 (-0.64), BMY: 76.72 (+0.52)

The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead, Regulus, AbbVie, The Medicines and GW Pharma
GWPH: 92.23 (-4.87), MDCO: 35.78 (-0.84), GILD: 86.15 (-0.48), RGLS: 3.36 (-0.13), ABBV: 64.86 (-0.64)

Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
Arpita Dutt - Zacks Investment Research - Wed Jun 29, 1:23PM CDT
Most biotech stocks were down reflecting uncertainty regarding the impact of Brexit on the sector especially companies which generate significant sales in the EU.
GWPH: 92.23 (-4.87), GILD: 86.15 (-0.48), MDCO: 35.78 (-0.84), ALXN: 123.74 (-1.61), RGLS: 3.36 (-0.13), ABBV: 64.86 (-0.64), XNCR: 18.22 (-0.07)

Infinity Regains Duvelisib Rights, Announces Restructuring
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 10:08AM CDT
Infinity Pharmaceuticals (INFI) regained rights to develop and commercialize duvelisib; the company plans to eliminate 100 positions across the organization.
PFE: 36.31 (+0.07), ABBV: 64.86 (-0.64), INFI: 1.37 (-0.05), BMY: 76.72 (+0.52)

Research Report Initiated on Select Major Drug Manufacturers Equities
ACCESSWIRE - Wed Jun 29, 8:18AM CDT
LONDON, UK / ACCESSWIRE / June 29, 2016 / Active Wall St announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Major industry. Companies recently under review include Pfizer, Merck, AbbVie, and Johnson & Johnson. See our complete report on Pfizer at:
JNJ: 122.99 (+0.07), MRK: 59.62 (+0.02), PFE: 36.31 (+0.07), ABBV: 64.86 (-0.64)

AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
PR Newswire - Wed Jun 29, 6:30AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a fourth Breakthrough Therapy Designation (BTD) for ibrutinib (IMBRUVICA®) as a potential treatment of chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy. The FDA also granted the therapy Orphan Drug Designation (ODD) for the condition. cGVHD is a severe and potentially life-threatening condition in which transplanted cells from the donor attack the patient's body.1 Patients may develop this common complication after undergoing allogeneic stem cell or bone marrow transplantation in which they receive cells from a donor.1 There are currently no therapies specifically approved for this condition. Most patients with cGVHD are prescribed glucocorticoids, a systemic steroid treatment that is able to act upon cells throughout the entire body;2 however, research shows that long-term use of steroids can lead to serious health complications.3
ABBV: 64.86 (-0.64)

Why Is Gilead Sciences (GILD) Stock Gaining Today?
Ryan McQueeney - Zacks Investment Research - Tue Jun 28, 11:59AM CDT
Gild Sciences (GILD) gained nearly 3.5% in morning trading today following the approval of its new hepatitis C drug.
GILD: 86.15 (-0.48), ABBV: 64.86 (-0.64)

Global Prostate Cancer Therapeutics Industry
PR Newswire - Mon Jun 27, 2:46PM CDT
This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Million by the following Segments: Hormone Therapy, and Other Therapies. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 76 companies including many key and niche players such as -
ABBV: 64.86 (-0.64)

Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 122.99 (+0.07), MU: 13.32 (+0.09), PXD: 154.21 (-2.29), GILD: 86.15 (-0.48), EOG: 83.89 (-1.25), AMGN: 160.64 (-1.32), ABBV: 64.85 (-0.65), GOOGL: 730.29 (-2.22), CVX: 106.55 (-0.23), MSFT: 53.71 (+0.50)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newfold Digital Revamps Leadership for Growth Surge

Steering into New Horizons with Fresh Leadership October 2026 marks a fresh chapter for Newfold Digital, as they shuffle the deck chairs a bit and ramp up for some ambitious growth endeavors. This web and commerce tech company decided it's time to bring a few heavy hitters on board. Starting this month, watch out for Sachin Puri taking the reins as Chief Executive...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Full Sail University Bags Billboard Music School Honor

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Protecting Your Family on Halloween: Safety Tips

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Aspen Dental Brings Comprehensive Care to Whiteville

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

CME Group Unveils First Baseball Futures Market

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...